Skip to main content
Xenon Pharmaceuticals Inc. logo

Xenon Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · XENE ISIN · CA98420N1050 LEI · 549300XV44Q9Z1MIPQ03 US Manufacturing
Open in API
Filings indexed 746 across all filing types
Latest filing 2023-11-09 Regulatory Filings
Country CA Canada
Listing US XENE

About Xenon Pharmaceuticals Inc.

https://www.xenon-pharma.com/

Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company dedicated to the discovery, clinical development, and commercialization of therapeutics for neurological and psychiatric disorders. The company leverages its expertise in human genetics and a deep understanding of ion channel biology to develop medicines that modulate ion channels, targeting the central and peripheral nervous systems. Its late-stage pipeline includes azetukalner, an investigational candidate being developed for the treatment of epilepsy and depression.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated November 9, 2023. It announces a press release regarding a clinical trial result failure by a partner company. The document includes a press release as an exhibit but does not contain financial statements or detailed financial data. The length is 3303 characters, which is relatively short and consistent with an announcement rather than a full report. The content is an event disclosure rather than a financial report, earnings release, or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2023-11-09 English
10-Q
Interim / Quarterly Report Q3 2023
2023-11-08 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events or updates by a company. The text specifically mentions that the company announced its financial results for the three and nine months ended September 30, 2023, via a press release attached as an exhibit. The document itself does not contain detailed financial statements or substantive financial data but rather references the press release. The length of the document is 4468 characters, which is relatively short and consistent with a regulatory announcement rather than a full financial report. According to the rules, if a document is short and announces or attaches a report (like a press release of financial results), it should be classified as a Regulatory Filing (RNS) rather than an Interim Report (IR) or Earnings Release (ER). The document is not a transcript, proxy, or other specific filing type. Therefore, the best classification is Regulatory Filings (RNS).
2023-11-08 English
4
Director's Dealing
2023-08-24 English
Regulatory Filings 2023
Regulatory Filings
2023-08-24 English
4
Director's Dealing
2023-08-11 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.